Trung Vu Nguyen

Trung Vu Nguyen

Auto-generated profile, based on publicly available information

Trung Vu Nguyen

Department of Orofacial Sciences, University of California San Francisco School of Dentistry San Francisco California USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2011 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
CNCuong Hung Nguyen
Cuong Hung Nguyen
AIAzumi Ishizaki
Azumi Ishizaki
PCPhan Thi Thu Chung
Phan Thi Thu Chung
HHHuyen Thi Hoang
Huyen Thi Hoang
TNTrung Vu Nguyen
Trung Vu Nguyen
HIHiroshi Ichimura
Hiroshi Ichimura
Hepatitis B virus (HBV) infection in Hai Phong, northern Vietnam, was characterized by analyzing the prevalence and genotype distribution of HBV as well as co-infection with human immunodeficiency virus type 1 (HIV-1) among five different risk groups for HIV infection. Plasma samples were collected from intravenous drug users (n = 760, anti-HIV-1 antibody positive rate: 35.9%), female sex workers (FSWs; n = 91, 23.1%), seafarers (n = 94, 0%), pregnant women (n = 200, 0.5%), and blood donors (n = 210, 2.9%) in 2007 [Ishizaki et al. (2009): AIDS Res Hum Retroviruses 25:175–182]. Samples were screened for the hepatitis B surface antigen (HBsAg) and anti-HBs antibody and analyzed genetically. The cumulative HBV incidence rate (HBsAg + anti-HBs) was 53.2% (10.7 + 42.5%) in intravenous drug users, 51.6% (11.0 + 40.6%) in FSWs, 54.3% (9.6 + 44.7%) in seafarers, 50.5% (12.5 + 38.0%) in pregnant women, and 51.0% (18.1 + 32.9%) in blood donors; there was no significant difference among these groups. Of 163 HBsAg-positive samples, 113 could be analyzed genetically. Phylogenetic analysis, based on the preS1 region, revealed genotype B4 was most prevalent (90/113; 79.6%), followed by C1 (17.7%), I1 (1.8%), and B2 (0.9%). There was no significant difference in HBV genotype distribution among different HIV infection-risk groups. The prevalence of HBsAg was 10.3% (31/301) in HIV-1-infected individuals and 12.5% (132/1,054) in non-HIV-1-infected individuals, which was not significant. In addition, no significant difference in HBV genotype distribution was observed between HBV/HIV-1 co-infected and HBV mono-infected groups. These results suggest that, although HBV and HIV-1 share modes of transmission, major transmission routes of HBV have been different from those of HIV-1 in Hai Phong, Vietnam. J. Med. Virol. 83:399–404, 2011.

1 March 2018 in Journal of Virology
Verified
Journal Article
Open access
PDF file
TCTakayuki Chikata
Takayuki Chikata
GTGiang Van Tran
Giang Van Tran
HMHayato Murakoshi
Hayato Murakoshi
TATomohiro Akahoshi
Tomohiro Akahoshi
YQYing Qi
Ying Qi
MTMasafumi Takiguchi
Masafumi Takiguchi
HIV-1-specific cytotoxic T cells (CTLs) play an important role in the control of HIV-1 subtype B or C infection. However, the role of CTLs in HIV-1 subtype A/E infection still remains unclear. Here we investigated the association of HLA class I alleles with clinical outcomes in treatment-naive Vietnamese infected with subtype A/E virus. We found that HLA-C*12:02 was significantly associated with lower plasma viral loads (pVL) and higher CD4 counts and that the HLA-A*29:01-B*07:05-C*15:05 haplotype was significantly associated with higher pVL and lower CD4 counts than those for individuals without these respective genotypes. Nine Pol and three Nef mutations were associated with at least one HLA allele in the HLA-A*29:01-B*07:05-C*15:05 haplotype, with a strong negative correlation between the number of HLA-associated Pol mutations and CD4 count as well as a positive correlation with pVL for individuals with these HLA alleles. The results suggest that the accumulation of mutations selected by CTLs restricted by these HLA alleles affects HIV control. IMPORTANCE Most previous studies on HLA association with disease progression after HIV-1 infection have been performed on cohorts infected with HIV-1 subtypes B and C, whereas few such population-based studies have been reported for cohorts infected with the Asian subtype A/E virus. In this study, we analyzed the association of HLA class I alleles with clinical outcomes for 536 HIV-1 subtype A/E-infected Vietnamese individuals. We found that HLA-C*12:02 is protective, while the HLA haplotype HLA-A*29:01-B*07:05-C*15:05 is deleterious. The individuals with HIV-1 mutations associated with at least one of the HLA alleles in the deleterious HLA haplotype had higher plasma viral loads and lower CD4 counts than those of individuals without the mutations, suggesting that viral adaptation and escape from HLA-mediated immune control occurred. The present study identifies a protective allele and a deleterious haplotype for HIV-1 subtype A/E infection which are different from those identified for cohorts infected with HIV-1 subtypes B and C.

4 May 2022 in Clinical Advances in Periodontics
Verified
Journal Article
Open access
HKHooshang Kashani
Hooshang Kashani
MVManali V. Vora
Manali V. Vora
RKRyutaro Kuraji
Ryutaro Kuraji
HFHoorshad Fathi‐Kelly
Hoorshad Fathi‐Kelly
TNTrung Nguyen
Trung Nguyen
YKYvonne L. Kapila
Yvonne L. Kapila
Introduction: Root coverage procedures are not always predictable, and outcomes depend on several factors. This technique provides a predictable alternative to managing facial gingival recessions.Case Series: A new grafting technique is introduced that requires no incisions at the recipient site, thereby preserving the integrity of the local blood supply to optimize the healing process. The graft is placed through the gingival sulcus via a molar or canine access (MOCA) approach, and there is minimal tension on the coronally advanced flap through use of suspension sutures. Thirteen non‐smoking patients, between the ages of 27 and 57, with Cairo RT1 facial recession were studied, with a follow‐up period of 1–60 weeks. This paper explains the step‐by‐step technique and highlights 13 cases.Conclusion: Complete root coverage was achieved in all 13 cases, although one case showed initial altered healing. While MOCA is technique sensitive, it provides optimal root coverage results. With no incisions at the recipient site, there is no uneven texture or scar formation, and healing proceeds with minimal interruption.Why is this case series new information? MOCA is a unique approach to introduce grafts into non‐incised sites of recession that can be one, two, or three teeth away at molars or canines. Non‐incised approach minimizes interruption to blood supply. Coronally advanced flaps are secured in place with composite‐fastened suspension sutures for tension‐free flap closure. What are the keys to successful management of these cases? Good quality and quantity of connective tissue graft Early diagnosis and treatment of recession Expert surgical technique What are the key limitations to the success of these cases? The quality of the donor site is variable among patients. A technique‐sensitive approach Advanced recession might warrant a second surgery.

12 November 2020 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
TNTrung V Nguyen
Trung V Nguyen
OOOnyebuchi J Ononogbu
Onyebuchi J Ononogbu
OEOliver U Egwim
Oliver U Egwim
FSFarnoush Saffari
Farnoush Saffari
JFJamie Ferrer
Jamie Ferrer
Purpose: Due to the multifaceted chemotherapy workflow within the hospital, many patients often experience delays in receiving their treatment. This study aims to evaluate the causes for chemotherapy administration delays and implement new methods to reduce delays from order release to chemotherapy administration on an inpatient oncology unit at a community-focused academic medical center. Methods: In this prospective quality improvement study, we developed a process map to track baseline time stamps and utilized performance improvement tools to identify causes for chemotherapy delays. Based on recognized areas for improvement, the Plan-Do-Study-Act (PDSA) model was used to implement one cycle of interventions. Chemotherapy orders were collected, and benchmark time stamps were documented from the electronic medical record. Results: The primary outcome for the number of chemotherapy delays, based on compliance rate, was reduced from 63/100 (63.0%) to 48/100 (48.0%), a 15% reduction (p = 0.046). Our primary outcome of chemotherapy delays, based on our institutional benchmark of <3 hours, did not show statistical significance. Median time from chemotherapy order release to administration decreased from 7.08 hours at baseline to 6.10 hours post-intervention, a 13.8% reduction (p < 0.0001). Median verification, preparation, and delivery times were all reduced post-intervention by 13.0% (p < 0.0001), 3.9% (p = 0.024), and 14.8% (p < 0.0001) respectively. Conclusions: This study allowed our institution to evaluate our current practice and reformulate the chemotherapy administration process. With the continuing education on the chemotherapy administration process and additional PDSA cycle interventions, it will help standardize our process and ultimately continue to reduce chemotherapy delays.